SI-BONE (SIBN) Q2 2026 earnings review
Operating Leverage Drives Profitability Inflection
SI-BONE delivered a textbook quarter of operating leverage. Revenue growth accelerated to 15.2% YoY (up from 11.2% in Q1), reaching $56.0M, while operating expenses grew just 7.7%. This disciplined cost control drove Adjusted EBITDA up 178% YoY to $2.8M and generated positive operating cash flow. Bolstered by the finalized CMS MS-DRG reimbursement catalyst for Granite and expanding physician adoption, management confidently raised the full-year revenue floor while lowering OpEx growth guidance. The transition from a cash-burning medtech to a profitable growth engine is now highly visible.
🐂 Bull Case
With an OpEx growth rate roughly half that of revenue growth, SI-BONE is systematically expanding its bottom line. Lowering FY26 OpEx guidance from 12.5% to 12.0% signals high confidence in sustained leverage.
CMS finalized the new MS-DRG family for complex spinal fusions using Granite. Effective October 1, this removes hospital cost barriers and acts as an immediate tailwind for Q4 and into 2027.
🐻 Bear Case
Despite positive Adjusted EBITDA, SI-BONE reported a $4.1M net loss. High stock-based compensation (~$6.0M this quarter) continues to weigh heavily on true GAAP profitability.
Gross margin ticked down slightly to 79.5% from 79.8% a year ago. As the company expands into trauma and ASCs, product mix shifts could cap margin expansion.
⚖️ Verdict: 🟢
Bullish. The company is accelerating top-line growth while maintaining tight operational discipline. With a massive reimbursement catalyst hitting in Q4 and a 3rd breakthrough device nearing launch, the forward setup is exceptionally strong.
Key Themes
Macro: CMS MS-DRG Finalization Alters Hospital Economics
A major macro and reimbursement catalyst was confirmed: CMS finalized the new MS-DRG family providing higher in-patient payments for complex spinal fusions incorporating iFuse Bedrock Granite. Effective October 1, this systemic change fundamentally improves hospital economics, removing cost as a primary objection and positioning Granite to become the standard of care.
Physician Engagement Reaches Record Density
Active U.S. physicians grew 19% YoY to 1,715. Crucially, this broader base is becoming more productive. Trailing 12-month average revenue per territory increased 5% to $2.2M. The company's "hybrid" sales model—blending direct reps with third-party agents—is driving deep adoption across SI joint, pelvic fixation, and trauma without requiring bloated sales headcount.
Tech Innovation: 3rd Breakthrough Device on Schedule
The innovation pipeline remains a primary growth engine. In June, SI-BONE submitted its 510(k) application for a third breakthrough device targeting one of the largest unmet needs in spine surgery. Slated for a Q4 launch, this specific technology represents a direct lever to expand the Total Addressable Market (TAM) outside of traditional SI fusion.
ASP Pressure from Mix Shift Contradicts Volume Story
While U.S. procedure volume grew an impressive 14.9%, U.S. revenue grew slightly slower at 14.7%. This data point contradicts the pure expansion narrative by highlighting slight Average Selling Price (ASP) degradation. As SI-BONE pushes aggressively into the interventional space and trauma—procedures that typically utilize fewer implants per case—ASP pressure will be a persistent, offsetting headwind to volume growth.
Stock-Based Compensation Suppresses GAAP Earnings
Management loudly champions the $2.8M in positive Adjusted EBITDA, but this non-GAAP metric obscures a harsh reality: SI-BONE printed nearly $6.0M in stock-based compensation (SBC) this quarter. SBC consumes over 10% of total revenue, keeping GAAP net income deeply negative (-$4.1M) and diluting shareholders despite operational cash flow improvements.
Gross Margin Hits a Ceiling
Gross margin decelerated slightly to 79.5% from 79.8% in the prior year period. Management has previously warned that near-term margins will face pressure from non-cash depreciation related to expanding surgical instrument trays for new product launches. Investors should not expect gross margin expansion to be a driver of future EPS upside.
Other KPIs
Accelerating. An incredible 178% YoY improvement from $1.0M in the prior year. This proves the business model is highly scalable once territory productivity crosses the $2M threshold. Operating cash flow also inflected positive at $0.8M.
Stable. Up sequentially by $1.3M from Q1. With positive operating cash flow, SI-BONE has eliminated near-term financing risk. The balance sheet is fortress-like relative to its cash burn, providing ample runway to fund the roll-out of the upcoming breakthrough device without equity dilution.
Accelerating. Grew 25.9% YoY, driven by the reception of iFuse TORQ and iFuse TORQ TNT. While it only represents ~5% of total sales, the rapid growth indicates that the European strategy—pulled forward from original 2027 timelines—is gaining meaningful traction.
Guidance
Accelerating. Management raised the lower bound of previous guidance ($230M - $233M). The midpoint implies roughly 15.5% YoY growth. Achieving this relies heavily on Q4 catalysts, including the October 1 MS-DRG implementation and the Smith + Nephew trauma partnership ramp.
Decelerating. Lowered from prior guidance of ~12.5%. This is a highly bullish signal; management is simultaneously raising the revenue floor while tightening the belt on spending, cementing the thesis of expanding operating leverage through the back half of the year.
Stable. Maintained from prior guidance. The slight expected dip from Q2's 79.5% reflects the anticipated depreciation costs associated with scaling surgical tray inventory to support the Smith + Nephew partnership and the upcoming breakthrough device launch.
Key Questions
Quantifying ASP Pressure
With U.S. procedure volumes growing faster than U.S. revenue, how much of this is driven by pure mix-shift to trauma/interventional versus defensive pricing actions in the ASC setting?
Smith & Nephew Ramp Cadence
Now that we are entering H2, what early quantitative indicators can you share regarding the Smith & Nephew partnership's penetration into Level 1 and Level 2 trauma centers?
3rd Breakthrough Device Economics
With the 510(k) submitted, how should we model the CapEx requirements for instrument trays in Q3/Q4 ahead of the launch, and what is the expected timeline to positive gross margin contribution for this specific product?